Ovarian cancer treatment is finally getting the precision it desperately needs—imagine a future where every woman with this disease receives exactly the right therapy, boosting survival rates and sparing unnecessary suffering. But here's the heart-wrenching reality: current methods often fall short, leaving some patients without the benefits they could have. Dive in as we explore a groundbreaking breakthrough that might change everything.
Let's break this down for those new to the topic. Ovarian cancer is notoriously tough to treat, especially since it often hides and spreads silently. One promising approach uses drugs called PARP inhibitors, which target cancers with specific weaknesses in their DNA repair mechanisms. These cancers are labeled 'HRD positive'—HRD stands for homologous recombination deficiency, a fancy term for flaws in how cells fix their genetic code. For women with this type of cancer, PARP inhibitors can be a game-changer, helping to slow or stop tumor growth.
However, not all patients fit neatly into this category. Clinicians have long observed that some women with 'HRD negative' tumors—those without the obvious DNA repair defect—still see real benefits from these inhibitors. On the flip side, others with HRD positive cancer don't respond as hoped. This inconsistency suggests hidden factors at play, like immune responses or inflammation, that influence how well the treatment works. It's frustrating, isn't it? And this is the part most people miss: relying solely on the HRD test might mean overlooking patients who could thrive with the right intervention.
Enter a team of researchers from RMIT University and the Walter and Eliza Hall Institute (WEHI), led by Distinguished Professor Magdalena Plebanski and Professor Clare Scott. They've developed an innovative blood test that promises to refine how we identify candidates for PARP inhibitor therapy. 'Until now, there hasn't been a straightforward way to pinpoint who'll truly benefit beyond the standard HRD assessment,' Plebanski explains, directing RMIT's Accelerator for Translational Research and Clinical Trials (ATRACT) Centre. In their SOLACE2 trial, this new test shone a light on immune markers that could forecast response more accurately, potentially revolutionizing patient selection.
But here's where it gets controversial: This approach challenges the gold standard HRD test, which relies on analyzing cancer tissue for DNA repair defects. While effective in many cases, it has limitations—it's not always possible to get enough tissue, the procedure is complex, and importantly, a cancer's DNA repair ability can shift over time, like a moving target. Critics might argue that ditching the tried-and-true HRD method for something unproven could lead to risks, such as missing patients who need urgent treatment. Yet, the researchers believe their blood-based test offers a real-time snapshot of the body's immune fight against cancer, making it more reliable and easier to administer. No more invasive biopsies for everyone—just a simple blood draw that checks for immune biomarkers signaling the influx of beneficial immune cells to battle tumors, alongside markers of inflammation that could fuel resistance.
Published in Nature Communications, the study's results are exciting: These RMIT-patented biomarkers, detected via a straightforward blood test, outperformed the HRD test in predicting who would benefit from PARP inhibitors in the SOLACE2 trial. Professor Scott, head of WEHI's Ovarian and Rare Cancer Laboratory and a key figure at ANZGOG, highlighted a crucial insight—how immune cells, especially effector T cells, migrate into tumors to destroy cancer cells plays a pivotal role. This is especially true in combination therapies. 'Understanding this migration could open doors to enhancing treatments by boosting these immune boosts,' Scott noted, drawing on her experience as a medical oncologist at major Melbourne hospitals.
Of course, this test isn't ready for prime time yet. It requires further validation and regulatory approvals before it can be used widely in clinics. But the potential is massive: Imagine identifying women most likely to succeed with PARP inhibitors right away, personalizing care to avoid ineffective treatments and their side effects. For instance, a patient who might have been deemed ineligible under the old system could now access life-extending therapy, turning a grim prognosis into a more hopeful outlook.
The SOLACE2 trial, a phase 2 study, provided broader insights too. Clinical lead Professor Chee Khoon Lee from the University of Sydney's NHMRC Clinical Trials Centre reported that an initial three-month 'immune priming' phase, followed by PARP inhibitors and immunotherapy, delayed ovarian cancer recurrence in some participants. While the trial's size limited definitive proof, it underscored the test's promise for tailoring treatments. Lee emphasized that this could ensure each woman gets the best possible therapy, potentially transforming outcomes for those diagnosed with this challenging disease.
Collaboration was key to this progress, as Dr. April Kartikasari, a RMIT Postdoctoral Research Fellow, pointed out. Coordinated by ANZGOG across multiple hospitals, the team's unified effort enabled personalized approaches at the earliest signs of recurrence. 'This isn't just about better drugs—it's about matching them to the right people at the right time,' Kartikasari said. As PARP inhibitors become standard first-line treatments for ovarian cancer, validating this blood test could refine who receives them, sharpening health outcomes for women worldwide.
Plebanski, also leading RMIT's Cancer, Ageing and Vaccines (CAVA) Laboratory, sees this as a stepping stone. 'We're making strides now, but our long-term vision includes novel drugs and vaccines to end the cycle of cancer's toll,' she shared. It's a reminder that science is iterative—every breakthrough builds on the last.
But let's stir the pot a bit: Is this new test a leap forward, or could it complicate things by adding yet another layer to already overburdened healthcare systems? Will insurance cover it, and what about accessibility in underserved areas? Do you think prioritizing immune markers over DNA tests will truly personalize cancer care, or might it sideline some patients? Share your opinions, agreements, or disagreements in the comments—your input could spark vital discussions!
Reference: Lee CK, Kartikasari AER, Bound NT, et al. Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. Nat Commun. 2025;16(1):9756. doi: 10.1038/s41467-025-64130-6 (https://doi.org/10.1038/s41467-025-64130-6)
This article has been republished from the following materials (https://www.rmit.edu.au/news/all-news/2025/jul/ovarian-cancer-test). Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here (https://www.technologynetworks.com/tn/editorial-policies#republishing).
